Exploring kinase inhibitors as therapies for human arenavirus infections

Future Virology

Volumn 3, Issue 3, 2008, Pages 243-251

  Vela, Eric M ^a   Bowick, Gavin C ^b   Herzog, Norbert K ^b   Aronson, Judith F ^b  

^a BATTELLE MEMORIAL INSTITUTE   (United States)

^b University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Antiviral therapeutics; Arenavirus; Hemorrhagic fever; Kinase inhibitors; Virology

Indexed keywords

CELL RECEPTOR; CLATHRIN; CONTACTIN; DYNAMIN II; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR PATHWAY SUBSTRATE 15; F ACTIN; GENISTEIN; PROTEIN KINASE INHIBITOR; RIBAVIRIN; TRANSCRIPTION FACTOR AP 2; TRANSFERRIN RECEPTOR; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VIRUS GLYCOPROTEIN;

ARENAVIRUS; ARTICLE; BIOLOGICAL WARFARE; DEATH; ENDOCYTOSIS; GUINEA PIG; HIGH THROUGHPUT SCREENING; HUMAN; JUNIN VIRUS; LIQUID CHROMATOGRAPHY; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MASS SPECTROMETRY; MEDICAL DECISION MAKING; MEDICAL RESEARCH; NONHUMAN; PICHINDE ARENAVIRUS; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; RECEPTOR BINDING; RNA VIRUS; TANDEM MASS SPECTROMETRY; TWO DIMENSIONAL GEL ELECTROPHORESIS; VIRUS CELL INTERACTION; VIRUS HEMORRHAGIC FEVER; VIRUS INHIBITION; VIRUS REPLICATION; VIRUS TRANSMISSION;

ARENAVIRUS; RNA VIRUSES; RODENTIA;

EID: 44149088837     PISSN: 17460794     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460794.3.3.243     Document Type: Article

References (42)

1. Charrel R, Feldmann H, Fulhorst C et al.: Phylogeny of New World arenaviruses based on the complete coding sequences of the small genomic segment identified an evolutionary lineage produced by intrasegmental recombination. Biochem. Biophys. Res. Commun. 296, 1118-1124 (2002).
2. Bolken T, Laquerre S, Zhang Y et al.: Identification and characterization of potent small molecule inhibitor of hemorrhagic fever New World arenaviruses. Antiviral Res. 69, 86-97 (2006).
3. Carrion R, Patterson J, Johnson C et al.: A ML29 reassortant virus protects guinea pigs against a distantly related Nigerian strain of Lassa virus and can provide sterilizing immunity. Vaccine 25, 4093-4102 (2007).
4. Castilla V, Larzabal M, Sgalippa N, Wachsman M, Coto C: Antiviral mode of action of a synthetic brassinosteroid against Junin virus replication. Antiviral Res. 68, 88-95 (2005).
5. Enria D, Briggiler A, Sanchez Z: Treatment of Argentine hemorrhagic fever. Antiviral Res. 78(1), 132-139 (2008).
6. Gowen B, Barnard D, Smee D et al.: Interferon Alfacon-1 protects hamsters from lethal Pichinde virus infection. Antimicrob. Agents Chemother. 49, 2378-2386 (2005).
7. Gowen B, Wong M, Jung K et al.: In vitro and vivo activities of T-705 against arenavirus and Bunyavirus infections. Antimicrob. Agents Chemother. 51, 3168-3176 (2007).
8. Vela E, Bowick G, Herzog N, Aronson J: Genistein treatment of cells inhibits arenavirus infection. Antiviral Res. 77, 153-156 (2008).
9. Bowick G, Fennewald S, Scott E et al.: Identification of differentially activated cell-signalling networks associated with Pichinde virus pathogenesis by using systems kinomics. J. Virology 81, 1923-1933 (2007).
10. Kuijl C, Savage NDL, Marsman M et al.: Intracellular bacterial growth is controlled by a kinase network around PKB/AKT1. Nature 450, 725-730 (2007).
11. Cao W, Henry M, Borrow P et al.: Identification of alpha-dystoglygan as a receptor for Lymphocytic choriomeningitis virus and Lassa fever virus. Science 282, 2079-2081 (1998).
12. Borrow P, Oldstone M: Mechanism of Lymphocytic choriomeningitis virus entry into cells. Virology 198 1-9 (1994).
13. Glushakova S, Lukashevich I: Early events in arenavirus replication are sensitive to lysosomotropic compounds. Arch. Virol. 104, 157-161 (1989).
14. Radoshitzky S, Abraham J, Spiropoulou C et al.: Transferrin receptor 1 is a cellular receptor for New World haemorrhagic fever arenaviruses. Nature 446, 92-96 (2007).
15. Martinez M, Cordo S, Candurra N: Characterization of Junin arenavirus cell entry. J. Gen. Virol. 88, 1776-1784 (2007).
16. Vela E, Zhang L, Colpitts T, Davey R, Aronson J: Arenavirus entry occurs through a cholesterol-dependent, non-caveolar, clathrin-mediated endocytic mechanism. Virology 369, 1-11 (2007).
17. Castilla V, Merisch S: Low pH-induced fusion of Vero cells infected with Junin virus. Arch. Virol. 141, 1307-1317 (1996).
18. Di Simone C, Zandonatti M, Buchmeier M: Acidic pH triggers LCMV membrane fusion activity and conformational change in the glycoprotein spike. Virology 198, 455-465 (1994).
19. Di Simone C, Buchmeier M: Kinetics and pH dependence of acid-induced structural changes in the Lymphoytic choriomeningitis virus glycoprotein complex. Virology 209, 3-9 (1995).
20. Benmerah A, Bayrou M, Cerf-Bensussan N, Dautry-Varsat A: Inhibition of clathrin-coated pit assembly by an Eps15 mutant. J. Cell Sci. 112, 1303-1311 (1999).
21. Conner S, Schmid S: Regulated portals of entry into the cell. Nature 422, 37-44 (2003).
22. Torrisi M, Lotti L, Belleudi F et al.: Eps15 is recruited to the plasma membrane upon epidermal growth factor receptor activation and localizes to components of the endocytic pathway during receptor internalization. Mol. Biol. Cell 10, 417-434 (1997).
23. McNiven M, Cao H, Pitts K, Yoon Y: The dynamin family of mechanoenzymes: pinching in new places. Trends Biochem. Sci. 25, 115-120 (2000).
24. Bowick G, Fennewald S, Elsom B et al.: Differential signaling networks induced by mild and lethal hemorrhagic fever virus infections. J. Virology 80, 10248-10252 (2006).
25. Fennewald S, Scott E, Zhang L et al.: Thioaptamer decoy targeting of Ap-1 proteins influences cytokine expression and the outcome of arenavirus infections. J. Gen. Virol. 88, 981-990 (2007).
26. Akiyama T, Ishida J. Nakagawa S et al.: Genistein, a specific inhibitor of tyrosine-specific protein kinases. J. Biol. Chem. 262, 5592-5595 (1987).
27. Damm E, Pelkmans L, Kartenbeck J et al.: Clathrin- and caveolin-1-independent endocytosis: entry of simain virus 40 into cells devoid of caveolae. J. Cell Biol. 168, 477-488 (2005).
28. Pelkmans L, Puntener D, Helenius A: Local actin polymerization and dynamin recruitment in SV40-induced Internalization of caveolae. Science 296, 535-539 (2002).
29. Duan W, Kuo I, Selvarajan S et al.: And inflammatory effects of genistein, a tyrosine kinase inhibitor, on a guinea pig model of asthma. Am. J. Respir. Crit. Care Med. 167, 185-192 (2003).
30. Tseng C, Lo H, Teng H. Lo W, Ker C: Elevated levels of plasma VEGF in patients with dengue hemorrhagic fever. FEMS Immunol. Med. Microbiol. 43, 99-102 (2005).
31. Quinn T, Peters K, De Vries C, Ferrara N, Williams L: Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium. Proc. Natl. Acad Sci. 90, 7533-7537 (1993).
32. Gille H, Kowalski J, Li B et al.: Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific vascular endothelial growth factor mutants. J. Biol. Chem. 276, 3222-3230 (2001).
33. Deininger M, Druker B: Specific targeted therapy of chronic myelogenous leukemia with imatinib. Pharmacol. Rev. 55, 401-423 (2003).
34. Das J, Chen P. Norris D et al.: 2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2- 6-]4-(hydroxyethyl)-1-piperazinyl)] -2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (dasatnib, BMS-354825) as a potent pan-Src kinase inhibitor. J. Med. Chem. 49, 6819-6832 (2006).
35. Zhou J, Khng J, Jasinghe V et al.: In vivo activity of ABT-869, a multi-target kinase inhibitor, against acute myeloid leukemia with wild-type FLT3 receptor. Leukemia Res. DOI: 10.1016/ j.leukres.2007.11.025 (2007) (Epub ahead of print).
36. Pao W, Miller V, Zakowski M et al.: EGF receptor gene mutations are common in lung cancers from never smoker's and are associated with sensitivity of tumors to gefitinib and irlotinib. Proc. Natl Acad. Sci. 101, 13306-13311 (2004).
37. Perez-Soler R, Chachoua A, Hammond L et al.: Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. Am. J. Clin. Oncol. 22, 3238-3247 (2004).
38. Lee M, Dominguez C: MAP kinase p38 inhibitors: clinical results and an intimate look at their interactions with p38alpha protein. Curr. Med. Chem. 12, 2979-2994 (2005).
39. Castoldi R, Pennella G, Saturno G et al.: Assessing and managing toxicities induced by kinase inhibitors. Curr Opin. Drug Discov. Devel. 10, 53-57 (2007).
40. Schang L, St. Vincent M, Lacasse J: Five years of progress on cyclin-dependent kinases and other cellular proteins as potential targets for antiviral drugs. Antivir. Chem. Chemother. 17, 293-320 (2006).
41. Schleiss M, Eickhoff J, Auerochs S et al.: Protein kinase inhibitors of the quinazoline class exert anti-cytomegaloviral activity in vitro and in vivo. Antiviral Res. DOI: 10.1016/ j.antiviral.2008.01.154 (2008) (Epub ahead of print).
42. Wang X, Huong S, Chlu M, Raab-Traub N, Huang E: Epidermal growth factor receptor is a cellular receptor for human cytomegalovirus. Nature 424, 456-461 (2003).